UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Breast cancer (BC) treatment (tx) with everolimus (EVE) and exemestane (EXE) in hormone receptor positive (HR+)/ HER2-negative (HER2−) postmenopausal women: Final analysis of the French observational TANGO study

Annals of oncology, 2018-10, Vol.29, p.viii109-viii109

2018

Volltextzugriff (PDF)

An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma

Annals of oncology, 2018-10, Vol.29, p.viii449-viii450

2018

Volltextzugriff (PDF)

1332P - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis

Annals of oncology, 2019-10, Vol.30, p.v542-v543

2019

Volltextzugriff (PDF)

Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: An open label, non randomized study

Annals of oncology, 2019-10, Vol.30, p.v546

2019

Volltextzugriff (PDF)

1338PFactors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: An open label, non randomized study

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1332PAn open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1338P - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: An open label, non randomized study

Annals of oncology, 2019-10, Vol.30, p.v546-v546

2019

Volltextzugriff (PDF)

An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis

Annals of oncology, 2019-10, Vol.30, p.v542-v543

2019

Volltextzugriff (PDF)

1260PAn open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

335PBreast cancer (BC) treatment (tx) with everolimus (EVE) and exemestane (EXE) in hormone receptor positive (HR+)/ HER2-negative (HER2−) postmenopausal women: Final analysis of the French observational TANGO study

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

In Memoriam Prof. Dr. W. Hallermann

Klinische Monatsblätter für Augenheilkunde, 2005-05, Vol.222 (5), p.444-444

Denden, A

2005

Volltextzugriff (PDF)

Electro-ophthalmological findings in so-called partial "retinopathia pigmentosa" (author's transl)

Klinische Monatsblätter für Augenheilkunde, 1977-11, Vol.171 (5), p.760

Denden, A

1977

Volltextzugriff (PDF)

ERG and EOG results in X-chromosomal vitreo-retinal degeneration (author transl)

Klinische Monatsblätter für Augenheilkunde, 1975-01, Vol.166 (1), p.35

Denden, A

1975

Volltextzugriff (PDF)

ERG und EOG bei der Spätform der multiplen vitelliformen Retinazysten des hinteren Augenpols

Ophthalmologica (Basel), 1972-06, Vol.164 (6), p.440-448

Denden, A.

1972

Volltextzugriff (PDF)

Influence of adaption level upon oscillatory potential in the electroretinogram (author's transl)

Albrecht von Graefes Archiv für klinische und experimentale Ophthalmologie, 1978-03, Vol.205 (4), p.279

Denden, A

1978

Volltextzugriff (PDF)

ERG- and EOG results in the vitreo-retinal syndrom of Jaffe (author's transl)

Albrecht von Graefes Archiv für klinische und experimentale Ophthalmologie, 1976-03, Vol.198 (3), p.265

Denden, A

1976

Volltextzugriff (PDF)

Critical correlation analysis of the subjective turgesence sensitivity of monocular dark adaptation of partial and anomalous color-disturbed eyes

Albrecht von Graefes Archiv für klinische und experimentale Ophthalmologie, 1966-12, Vol.171 (3), p.217-233

Denden, A

1966

Volltextzugriff (PDF)

Flimmer potential in the determination of photopic spectral sensitivity in normal trichromatism and congenital dichromatatopsia

Albrecht von Graefes Archiv für Ophthalmologie, 1962, Vol.165, p.1-19

DENDEN, A

1962

Volltextzugriff (PDF)

Fluoreszenzangiographie bei den multiplen vitelliformen Retinazysten des hinteren Augenpols

Ophthalmologica (Basel), 1973, Vol.166 (2), p.94-104

1973

Volltextzugriff (PDF)

An unusual form of cogwheel macula degeneration: central and paramacular alveolar pigment epitheliopathy (author's transl)

Klinische Monatsblätter für Augenheilkunde, 1978-09, Vol.173 (3), p.419

1978

Volltextzugriff (PDF)

Clinical contribution to Jaffe's syndrome (author's transl)

Klinische Monatsblätter für Augenheilkunde, 1976-02, Vol.168 (2), p.235

1976

Volltextzugriff (PDF)

Electro-ophthalmological examination results in fundus heterotopicus (author's transl)

Klinische Monatsblätter für Augenheilkunde, 1977-06, Vol.170 (6), p.925

Denden, A

1977

Volltextzugriff (PDF)

Heterotopic fundus (author's transl)

Klinische Monatsblätter für Augenheilkunde, 1976-07, Vol.169 (1), p.38

Denden, A

1976

Volltextzugriff (PDF)

ber den Einflu des Adaptationsniveaus auf die oszillierenden ERG-Potentiale (o.P.)

Albrecht von Graefes Archiv f r Klinische und Experimentelle Ophthalmologie, 1978, Vol.205 (4), p.279-288

Denden, A.

1978

Volltextzugriff (PDF)

ERG- and EOG-examination results in cases of toxocara canis retinochorioiditis (author's transl)

Klinische Monatsblätter für Augenheilkunde, 1974-10, Vol.165 (4), p.617

Denden, A

1974

Volltextzugriff (PDF)

1 – 25 von 304

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(172)
Mit Volltextzugriff
(162)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Breast cancer (BC) treatment (tx) with everolimus (EVE) and exemestane (EXE) in hormone receptor positive (HR+)/ HER2-negative (HER2−) postmenopausal women: Final analysis of the French observational TANGO study

An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma

1332P - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis

Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: An open label, non randomized study

1338PFactors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: An open label, non randomized study

1332PAn open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis

1338P - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: An open label, non randomized study

An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis

1260PAn open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma

335PBreast cancer (BC) treatment (tx) with everolimus (EVE) and exemestane (EXE) in hormone receptor positive (HR+)/ HER2-negative (HER2−) postmenopausal women: Final analysis of the French observational TANGO study

In Memoriam Prof. Dr. W. Hallermann

Electro-ophthalmological findings in so-called partial "retinopathia pigmentosa" (author's transl)

ERG and EOG results in X-chromosomal vitreo-retinal degeneration (author transl)

ERG und EOG bei der Spätform der multiplen vitelliformen Retinazysten des hinteren Augenpols

Influence of adaption level upon oscillatory potential in the electroretinogram (author's transl)

ERG- and EOG results in the vitreo-retinal syndrom of Jaffe (author's transl)

Critical correlation analysis of the subjective turgesence sensitivity of monocular dark adaptation of partial and anomalous color-disturbed eyes

Flimmer potential in the determination of photopic spectral sensitivity in normal trichromatism and congenital dichromatatopsia

Fluoreszenzangiographie bei den multiplen vitelliformen Retinazysten des hinteren Augenpols

An unusual form of cogwheel macula degeneration: central and paramacular alveolar pigment epitheliopathy (author's transl)

Clinical contribution to Jaffe's syndrome (author's transl)

Electro-ophthalmological examination results in fundus heterotopicus (author's transl)

Heterotopic fundus (author's transl)

ber den Einflu des Adaptationsniveaus auf die oszillierenden ERG-Potentiale (o.P.)

ERG- and EOG-examination results in cases of toxocara canis retinochorioiditis (author's transl)

Suchergebnisse filtern